Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Valued on Recurring Basis

We measure cash, cash equivalents, marketable securities and our liability classified warrants at fair value on a recurring basis. The fair values of such assets were as follows for December 31, 2021 and 2020 (in thousands):

 

       Fair Value Measurements Using 
   Balance at
December 31, 2021		  

Quoted Prices in Active Markets for Identical Assets

(Level 1)

  

Significant Other
Observable Inputs
(Level 2)

  

Significant
Unobservable Inputs

(Level 3)

 
Assets:                    
Cash and cash equivalents  $55,742   $55,742   $-   $- 
Marketable securities   2,616    2,616    -    - 
                     
Liabilities:                    
Lineage Warrants   -    -    -    - 
Cell Cure Warrants   227    -    -    227 

 

       Fair Value Measurements Using 
   Balance at
December 31, 2020		  

Quoted Prices in Active Markets for Identical Assets

(Level 1)

  

Significant Other
Observable Inputs

(Level 2)

  

Significant
Unobservable Inputs
(Level 3)

 
Assets:                    
Cash and cash equivalents  $32,585   $32,585   $-   $- 
Marketable securities   8,977    8,977    -    - 
                     
Liabilities:                    
Lineage Warrants   1    -    -    1 
Cell Cure Warrants   437    -    -    437 
Schedule of Changes In Fair Value

The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments:

 

(Dollars in thousands) 

Cell Cure

Warrants

  

Lineage

Warrants

   Total 
Balance as of December 31, 2020  $437   $1   $438 
Change in fair value and other adjustments   (210)   -    (210)
Expiration of warrants   -    (1)   (1)
Balance as of December 31, 2021  $227   $-   $227